42 studies found for:    acorda
Show Display Options
Rank Status Study
1 Completed Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
Condition: Multiple Sclerosis
Intervention: Drug: BIIB041 (Fampridine-SR)
2 Completed
Has Results
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine-SR
3 Completed
Has Results
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine-SR  b.i.d. (Twice Daily)
4 Recruiting A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke
Condition: Post-Ischemic Stroke
Interventions: Drug: Placebo;   Drug: dalfampridine-ER 7.5mg;   Drug: dalfampridine-ER 10mg
5 Recruiting An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures
Condition: Epilepsy
Intervention: Drug: diazepam nasal spray
6 Recruiting Randomized Safety Study of CVT-301 Compared to an Observational Control Group
Condition: Idiopathic Parkinson's Disease
Interventions: Drug: CVT-301;   Other: Observational cohort
7 Recruiting Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Condition: Idiopathic Parkinson's Disease
Intervention: Drug: CVT-301
8 Recruiting Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Condition: Idiopathic Parkinson's Disease
Intervention: Drug: CVT-301
9 Completed An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: rHIgM22
10 Recruiting A Study to Determine the Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)
Condition: Refractory Epilepsy
Interventions: Drug: diazepam nasal spray;   Drug: diazepam rectal gel
11 Recruiting An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study
Condition: Post-ischemic Stroke
Interventions: Drug: dalfampridine-ER 7.5 mg;   Drug: dalfampridine-ER 10 mg
12 Recruiting An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
Condition: Multiple Sclerosis, Acute Relapsing
Interventions: Drug: rHIgM22;   Drug: Placebo
13 Active, not recruiting A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure
Condition: Heart Failure
Interventions: Other: Placebo;   Drug: GGF2;   Drug: Midazolam
14 Completed
Has Results
A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
Condition: Spasticity
Interventions: Drug: Tizanidine;   Drug: Placebo;   Drug: Moxifloxacin
15 Completed Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
Condition: Idiopathic Parkinson's Disease
Interventions: Drug: CVT-301;   Drug: Placebo
16 Completed A Study of AC105 in Patients With Acute Traumatic Spinal Cord Injury
Condition: Acute Spinal Cord Injury
Interventions: Drug: AC105;   Other: Placebo
17 Completed
Has Results
Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury
Conditions: Spinal Cord Injury;   Muscle Spasticity
Interventions: Drug: Fampridine-SR;   Drug: Placebo
18 Completed
Has Results
A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Condition: Ischemic Stroke
Interventions: Drug: placebo/dalfampridine-ER;   Drug: dalfampridine-ER/placebo
19 Completed
Has Results
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
Condition: Cerebral Palsy (CP)
Interventions: Drug: dalfampridine-ER 10mg;   Other: Placebo
20 Terminated
Has Results
Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy
Condition: Spasticity Due to Cerebral Palsy
Intervention: Drug: Zanaflex Capsules

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years